These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28036266)

  • 1. Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.
    Seth A; Lee H; Cho MY; Park C; Korm S; Lee JY; Choi I; Lim YT; Hong KS
    Oncotarget; 2017 Jan; 8(3):5371-5381. PubMed ID: 28036266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
    Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
    Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
    Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
    Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy.
    Seth A; Heo MB; Lim YT
    Biomaterials; 2014 Sep; 35(27):7992-8001. PubMed ID: 24954733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.
    Kim H; Griffith TS; Panyam J
    J Pharmacol Exp Ther; 2019 Sep; 370(3):715-724. PubMed ID: 30610006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
    Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
    J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy.
    Heo MB; Kim SY; Yun WS; Lim YT
    Int J Nanomedicine; 2015; 10():5981-92. PubMed ID: 26451105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124.
    Molavi O; Ma Z; Hamdy S; Lavasanifar A; Samuel J
    Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):214-21. PubMed ID: 18798092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy.
    Dang BN; Duwa R; Lee S; Kwon TK; Chang JH; Jeong JH; Yook S
    J Control Release; 2024 Aug; 372():587-608. PubMed ID: 38942083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
    Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.
    Ma F; Zhang J; Zhang J; Zhang C
    Cell Mol Immunol; 2010 Sep; 7(5):381-8. PubMed ID: 20543857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
    Dumitru CD; Antonysamy MA; Gorski KS; Johnson DD; Reddy LG; Lutterman JL; Piri MM; Proksch J; McGurran SM; Egging EA; Cochran FR; Lipson KE; Tomai MA; Gullikson GW
    Cancer Immunol Immunother; 2009 Apr; 58(4):575-87. PubMed ID: 18791716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
    Schölch S; Rauber C; Tietz A; Rahbari NN; Bork U; Schmidt T; Kahlert C; Haberkorn U; Tomai MA; Lipson KE; Carretero R; Weitz J; Koch M; Huber PE
    Oncotarget; 2015 Mar; 6(7):4663-76. PubMed ID: 25609199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.
    Schmid D; Park CG; Hartl CA; Subedi N; Cartwright AN; Puerto RB; Zheng Y; Maiarana J; Freeman GJ; Wucherpfennig KW; Irvine DJ; Goldberg MS
    Nat Commun; 2017 Nov; 8(1):1747. PubMed ID: 29170511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
    Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
    Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses.
    Dowling DJ; Scott EA; Scheid A; Bergelson I; Joshi S; Pietrasanta C; Brightman S; Sanchez-Schmitz G; Van Haren SD; Ninković J; Kats D; Guiducci C; de Titta A; Bonner DK; Hirosue S; Swartz MA; Hubbell JA; Levy O
    J Allergy Clin Immunol; 2017 Nov; 140(5):1339-1350. PubMed ID: 28343701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses.
    Nuhn L; De Koker S; Van Lint S; Zhong Z; Catani JP; Combes F; Deswarte K; Li Y; Lambrecht BN; Lienenklaus S; Sanders NN; David SA; Tavernier J; De Geest BG
    Adv Mater; 2018 Nov; 30(45):e1803397. PubMed ID: 30276880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.